S6 Ep35: Hurvitz Reviews Pivotal Data From 2021, Previews Year Ahead in HER2+ Metastatic Breast Cancer

Dr Hurvitz sheds light on shifts in practice patterns in HER2-positive breast cancer in light of data that emerged in 2021, remaining questions regarding treatment sequencing, the importance of updates to the National Comprehensive Cancer Network guidelines in metastatic HER2-positive breast cancer, and future directions to keep an eye on in 2022.